The glucagon-like peptide-1 receptor (GLP-1R) agonists semaglutide and liraglutide are used for type 2 diabetes and have proven clinically successful in regulating blood glucose levels, but adverse drug reactions (ADRs) have ranged from nausea and diarrhea to pancreatitis.